Article Text

Download PDFPDF

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis
  1. C Popa1,2,
  2. M G Netea2,
  3. T Radstake1,
  4. J W M Van der Meer2,
  5. A F H Stalenhoef2,
  6. P L C M van Riel1,
  7. P Barerra1
  1. 1Department of Rheumatology, University Medical Centre St Radboud, Nijmegen, The Netherlands
  2. 2Department of Internal Medicine, University Medical Centre St Radboud, Nijmegen, The Netherlands
  1. Correspondence to:
    Dr P Barrera
    Rheumatology Department, UMC St Radboud, Geert Grooteplein 8, PO Box 9101 6500 HB Nijmegen, The Netherlands; P.Barrerareuma.umcn.nl

Abstract

Background: Tumour necrosis factor (TNF) is known to increase the concentrations of interleukin (IL) 6 and C reactive protein (CRP) and to induce proatherogenic changes in the lipid profile and may increase the cardiovascular risk of patients with rheumatoid arthritis (RA) and other inflammatory disorders.

Objective: To assess whether anti-TNF therapy modifies the cardiovascular risk profile in patients with RA.

Methods: The lipoprotein spectrum and the inflammation markers CRP and IL6 were investigated in 33 patients with RA treated with human anti-TNF monoclonal antibodies (D2E7, adalimumab, Humira) and 13 patients with RA given placebo, before and after 2 weeks’ treatment.

Results: In the anti-TNF treated group, the mean (SD) concentrations of HDL-cholesterol were significantly higher after 2 weeks’ treatment (0.86 (0.30) mmol/l v 0.98 (0.33) mmol/l, p<0.01), whereas LDL and triglyceride levels were not significantly changed. Additionally, a significant decrease in CRP (86.1 (54.4) mg/l v 35.4 (35.0) mg/l, p<0.0001), and IL6 (88.3 (60.5) pg/ml v 42.3 (40.7) pg/ml, p<0.001) concentrations was seen in this group. No changes in lipid profile, IL6, or CRP levels were seen in the placebo group.

Conclusions: TNF neutralisation with monoclonal anti-TNF antibodies increased HDL-cholesterol levels and decreased CRP and IL6 levels after 2 weeks. Therefore this treatment may improve the cardiovascular risk profile of patients with RA.

  • CRP, C reactive protein
  • DAS, Disease Activity Score
  • HDL, high density lipoprotein
  • IL, interleukin
  • LDL, low density lipoprotein
  • RA, rheumatoid arthritis
  • TG, triglyceride
  • TNFα, tumour necrosis factor α
  • anti-tumour necrosis factor α
  • lipoproteins
  • rheumatoid arthritis
  • risk factors
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.